A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-09-06

AUTHORS

Akihiko Izumi, Takayoshi Tachibana, Taiki Ando, Masatsugu Tanaka, Heiwa Kanamori, Hideaki Nakajima

ABSTRACT

This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD. More... »

PAGES

69-76

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4

DOI

http://dx.doi.org/10.1007/s12185-021-03217-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1140912417

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34490598


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatic Veno-Occlusive Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Inotuzumab Ozogamicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Izumi", 
        "givenName": "Akihiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tachibana", 
        "givenName": "Takayoshi", 
        "id": "sg:person.01074653417.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ando", 
        "givenName": "Taiki", 
        "id": "sg:person.010621551621.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010621551621.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Masatsugu", 
        "id": "sg:person.01171141246.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanamori", 
        "givenName": "Heiwa", 
        "id": "sg:person.01060176576.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakajima", 
        "givenName": "Hideaki", 
        "id": "sg:person.010061552415.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061552415.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2402922", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052214299", 
          "https://doi.org/10.1038/sj.leu.2402922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-019-02749-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122120596", 
          "https://doi.org/10.1007/s12185-019-02749-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2016.130", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017627248", 
          "https://doi.org/10.1038/bmt.2016.130"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.351", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050351263", 
          "https://doi.org/10.1038/leu.2011.351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2015.52", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003530776", 
          "https://doi.org/10.1038/bmt.2015.52"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-60761-629-0_13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023260237", 
          "https://doi.org/10.1007/978-1-60761-629-0_13"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-09-06", 
    "datePublishedReg": "2021-09-06", 
    "description": "This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27\u00a0years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1\u00a0year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-021-03217-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "115"
      }
    ], 
    "keywords": [
      "hematopoietic cell transplantation", 
      "veno-occlusive disease", 
      "allogeneic hematopoietic cell transplantation", 
      "acute lymphoblastic leukemia", 
      "inotuzumab ozogamicin", 
      "cell transplantation", 
      "lymphoblastic leukemia", 
      "progression-free survival rates", 
      "single-center retrospective study", 
      "negative minimal residual disease", 
      "post-HCT complications", 
      "complete hematological remission", 
      "minimal residual disease", 
      "salvage therapy", 
      "salvage chemotherapy", 
      "evaluable patients", 
      "maintenance therapy", 
      "disease remission", 
      "hematological remission", 
      "consecutive patients", 
      "case series", 
      "retrospective study", 
      "residual disease", 
      "favorable outcome", 
      "patients", 
      "eligibility criteria", 
      "survival rate", 
      "ozogamicin", 
      "remission", 
      "transplantation", 
      "therapy", 
      "leukemia", 
      "high rate", 
      "disease", 
      "further investigation", 
      "comprehensive treatment", 
      "iNO", 
      "chemotherapy", 
      "complications", 
      "death", 
      "outcomes", 
      "treatment", 
      "study", 
      "rate", 
      "years", 
      "criteria", 
      "investigation", 
      "series", 
      "cycle"
    ], 
    "name": "A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation", 
    "pagination": "69-76", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1140912417"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-021-03217-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34490598"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-021-03217-4", 
      "https://app.dimensions.ai/details/publication/pub.1140912417"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_914.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-021-03217-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      22 PREDICATES      99 URIs      85 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-021-03217-4 schema:about N1aaff6e9c40e4691910534137b777e0c
2 N220408b9215d455a88d57c5f1d1e4713
3 N2dc95c628a2c4f6ebb9c6ee81d056cd5
4 N3eadc639fecd4f68ba151baea9fb3bcb
5 N4d28c06b491f4d5faccf0b9e04b922f5
6 N4fc799791ac34757a0418e78e3d3a921
7 N66d00f7dc1d344c398844d87b45ac680
8 N7560686a78b146d39e406457cefbd8f5
9 N783ed8cd855d4ed99863ecaa41cebe06
10 N821c1abaf17045aeb8a2a1716eef75b7
11 N8381a5e6ecc449c69347adb04deb1dcf
12 N94c6c4bcd91a4efcbe09502eb4e9f093
13 Ncbb7e5305cf04952b16d68d817322d8a
14 Ne168d037868f4f23a686be9e6f0099d4
15 Ne3602896f7994d318f233bbefcca92d3
16 Nebcaf2eb088e4c33b01854f7747dd9ff
17 Nec6a1b13e02242869f05a5b885392c6c
18 Nf8e6e07cf34544e7a66b36de3f73b5b0
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N82b914adf7c444c4867a3d8795adb045
22 schema:citation sg:pub.10.1007/978-1-60761-629-0_13
23 sg:pub.10.1007/s12185-019-02749-0
24 sg:pub.10.1038/bmt.2015.52
25 sg:pub.10.1038/bmt.2016.130
26 sg:pub.10.1038/leu.2011.351
27 sg:pub.10.1038/sj.leu.2402922
28 schema:datePublished 2021-09-06
29 schema:datePublishedReg 2021-09-06
30 schema:description This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD.
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree false
34 schema:isPartOf N517f4741e8e542bf9cf7600b4b224da4
35 Nc3e09e20fecf447788c0447c911b08c6
36 sg:journal.1076985
37 schema:keywords acute lymphoblastic leukemia
38 allogeneic hematopoietic cell transplantation
39 case series
40 cell transplantation
41 chemotherapy
42 complete hematological remission
43 complications
44 comprehensive treatment
45 consecutive patients
46 criteria
47 cycle
48 death
49 disease
50 disease remission
51 eligibility criteria
52 evaluable patients
53 favorable outcome
54 further investigation
55 hematological remission
56 hematopoietic cell transplantation
57 high rate
58 iNO
59 inotuzumab ozogamicin
60 investigation
61 leukemia
62 lymphoblastic leukemia
63 maintenance therapy
64 minimal residual disease
65 negative minimal residual disease
66 outcomes
67 ozogamicin
68 patients
69 post-HCT complications
70 progression-free survival rates
71 rate
72 remission
73 residual disease
74 retrospective study
75 salvage chemotherapy
76 salvage therapy
77 series
78 single-center retrospective study
79 study
80 survival rate
81 therapy
82 transplantation
83 treatment
84 veno-occlusive disease
85 years
86 schema:name A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation
87 schema:pagination 69-76
88 schema:productId N811829214907432bbe7591f002b1115f
89 N8a86e4bf714c42049659e9ca74e44948
90 N92312fc1d4fc4b6686d5fa5c9cd1668d
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140912417
92 https://doi.org/10.1007/s12185-021-03217-4
93 schema:sdDatePublished 2022-05-20T07:38
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher Nfd497195365b41ba9ea2beb5726899c6
96 schema:url https://doi.org/10.1007/s12185-021-03217-4
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N1aaff6e9c40e4691910534137b777e0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Inotuzumab Ozogamicin
102 rdf:type schema:DefinedTerm
103 N220408b9215d455a88d57c5f1d1e4713 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Female
105 rdf:type schema:DefinedTerm
106 N2dc95c628a2c4f6ebb9c6ee81d056cd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Humans
108 rdf:type schema:DefinedTerm
109 N380282e5bdf74954aefbbde2f52272a7 rdf:first sg:person.01171141246.33
110 rdf:rest N42e5d955c79a405b90149cc29111819e
111 N3eadc639fecd4f68ba151baea9fb3bcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Retrospective Studies
113 rdf:type schema:DefinedTerm
114 N41a992381f37486880ae313daff9544f rdf:first sg:person.01074653417.74
115 rdf:rest N473e5eed8bd14317a8cfb79a0833298d
116 N42e5d955c79a405b90149cc29111819e rdf:first sg:person.01060176576.11
117 rdf:rest Ne2d86d99323a480f99afa42b0e3edb09
118 N473e5eed8bd14317a8cfb79a0833298d rdf:first sg:person.010621551621.49
119 rdf:rest N380282e5bdf74954aefbbde2f52272a7
120 N4d28c06b491f4d5faccf0b9e04b922f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Salvage Therapy
122 rdf:type schema:DefinedTerm
123 N4fc799791ac34757a0418e78e3d3a921 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Middle Aged
125 rdf:type schema:DefinedTerm
126 N517f4741e8e542bf9cf7600b4b224da4 schema:volumeNumber 115
127 rdf:type schema:PublicationVolume
128 N66d00f7dc1d344c398844d87b45ac680 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Remission Induction
130 rdf:type schema:DefinedTerm
131 N7560686a78b146d39e406457cefbd8f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Recurrence
133 rdf:type schema:DefinedTerm
134 N783ed8cd855d4ed99863ecaa41cebe06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Hematopoietic Stem Cell Transplantation
136 rdf:type schema:DefinedTerm
137 N811829214907432bbe7591f002b1115f schema:name dimensions_id
138 schema:value pub.1140912417
139 rdf:type schema:PropertyValue
140 N821c1abaf17045aeb8a2a1716eef75b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Treatment Outcome
142 rdf:type schema:DefinedTerm
143 N82b914adf7c444c4867a3d8795adb045 rdf:first Ndc24b6e7f71d4519ad09193c187d238b
144 rdf:rest N41a992381f37486880ae313daff9544f
145 N8381a5e6ecc449c69347adb04deb1dcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Precursor Cell Lymphoblastic Leukemia-Lymphoma
147 rdf:type schema:DefinedTerm
148 N8a86e4bf714c42049659e9ca74e44948 schema:name doi
149 schema:value 10.1007/s12185-021-03217-4
150 rdf:type schema:PropertyValue
151 N92312fc1d4fc4b6686d5fa5c9cd1668d schema:name pubmed_id
152 schema:value 34490598
153 rdf:type schema:PropertyValue
154 N94c6c4bcd91a4efcbe09502eb4e9f093 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hepatic Veno-Occlusive Disease
156 rdf:type schema:DefinedTerm
157 Nc3e09e20fecf447788c0447c911b08c6 schema:issueNumber 1
158 rdf:type schema:PublicationIssue
159 Ncbb7e5305cf04952b16d68d817322d8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Adolescent
161 rdf:type schema:DefinedTerm
162 Ndc24b6e7f71d4519ad09193c187d238b schema:affiliation grid-institutes:grid.414944.8
163 schema:familyName Izumi
164 schema:givenName Akihiko
165 rdf:type schema:Person
166 Ne168d037868f4f23a686be9e6f0099d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Transplantation, Homologous
168 rdf:type schema:DefinedTerm
169 Ne2d86d99323a480f99afa42b0e3edb09 rdf:first sg:person.010061552415.35
170 rdf:rest rdf:nil
171 Ne3602896f7994d318f233bbefcca92d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Disease-Free Survival
173 rdf:type schema:DefinedTerm
174 Nebcaf2eb088e4c33b01854f7747dd9ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Young Adult
176 rdf:type schema:DefinedTerm
177 Nec6a1b13e02242869f05a5b885392c6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Adult
179 rdf:type schema:DefinedTerm
180 Nf8e6e07cf34544e7a66b36de3f73b5b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Male
182 rdf:type schema:DefinedTerm
183 Nfd497195365b41ba9ea2beb5726899c6 schema:name Springer Nature - SN SciGraph project
184 rdf:type schema:Organization
185 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
186 schema:name Medical and Health Sciences
187 rdf:type schema:DefinedTerm
188 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
189 schema:name Oncology and Carcinogenesis
190 rdf:type schema:DefinedTerm
191 sg:journal.1076985 schema:issn 0925-5710
192 1865-3774
193 schema:name International Journal of Hematology
194 schema:publisher Springer Nature
195 rdf:type schema:Periodical
196 sg:person.010061552415.35 schema:affiliation grid-institutes:grid.268441.d
197 schema:familyName Nakajima
198 schema:givenName Hideaki
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061552415.35
200 rdf:type schema:Person
201 sg:person.01060176576.11 schema:affiliation grid-institutes:grid.414944.8
202 schema:familyName Kanamori
203 schema:givenName Heiwa
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11
205 rdf:type schema:Person
206 sg:person.010621551621.49 schema:affiliation grid-institutes:grid.414944.8
207 schema:familyName Ando
208 schema:givenName Taiki
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010621551621.49
210 rdf:type schema:Person
211 sg:person.01074653417.74 schema:affiliation grid-institutes:grid.414944.8
212 schema:familyName Tachibana
213 schema:givenName Takayoshi
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74
215 rdf:type schema:Person
216 sg:person.01171141246.33 schema:affiliation grid-institutes:grid.414944.8
217 schema:familyName Tanaka
218 schema:givenName Masatsugu
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33
220 rdf:type schema:Person
221 sg:pub.10.1007/978-1-60761-629-0_13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023260237
222 https://doi.org/10.1007/978-1-60761-629-0_13
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s12185-019-02749-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122120596
225 https://doi.org/10.1007/s12185-019-02749-0
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/bmt.2015.52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003530776
228 https://doi.org/10.1038/bmt.2015.52
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/bmt.2016.130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017627248
231 https://doi.org/10.1038/bmt.2016.130
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/leu.2011.351 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050351263
234 https://doi.org/10.1038/leu.2011.351
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.leu.2402922 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052214299
237 https://doi.org/10.1038/sj.leu.2402922
238 rdf:type schema:CreativeWork
239 grid-institutes:grid.268441.d schema:alternateName Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
240 schema:name Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
241 rdf:type schema:Organization
242 grid-institutes:grid.414944.8 schema:alternateName Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan
243 schema:name Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...